The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1005
July 18, 1997
View Complete Issue         Table of Contents 2019 
Tiludronate for Paget's Disease of Bone
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Tiludronate for Paget's Disease of Bone
July 18, 1997 (Issue: 1005)
Tiludronate (Skelid - Sanofi), a chloro-4-phenylthiomethylene bisphosphonate, has been approved by the US Food and Drug Administration (FDA) for treatment of Paget's disease of bone. Characterized by excessive bone resorption and disorganized bone ...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Tiludronate for Paget's Disease of Bone
Article code: 1005a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.